Parabilis Medicines, Inc. (PBLS)
| Market Cap | 3.22B |
| Revenue (ttm) | n/a |
| Net Income | -209.71M |
| EPS | -67.09 |
| Shares Out | 118.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,035,847 |
| Open | 29.86 |
| Previous Close | 30.31 |
| Day's Range | 26.88 - 32.47 |
| 52-Week Range | 26.61 - 34.47 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About PBLS
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-ca... [Read more]
Financial Performance
Financial StatementsNews
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines address...
Parabilis Medicines off highs, but still up over 50% from IPO price
The shares in afternoon trading are up $10.67 from the $20.00 offer price to $30.67.
Parabilis Medicines opens at $33.35, IPO priced at $20.00
Parabilis Medicines (PBLS) priced 33.5M shares at $20.00. The deal size was increased to 33.5M shares and priced above the $17.00-$19.00 target range. Leerink, BofA, Evercore ISI, Guggenheim and LifeS...
Parabilis Medicines 33.5M share IPO priced at $20.00
The deal size was increased to 33.5M shares and priced above the $17.00-$19.00 target range. Leerink, BofA, Evercore ISI, Guggenheim and LifeSci Capital are acting as joint book running managers…
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines address...
Parabilis Medicines aims to raise $633 million in upsized US IPO
Biopharmaceutical company Parabilis Medicines said on Tuesday it was aiming to raise as much as $633.3 million in its upsized initial public offering in the U.S.
Parabilis Medicines aims to raise up to $475 million in US IPO
Biopharmaceutical company Parabilis Medicines said on Thursday it is aiming to raise as much as $475 million in its U.S. initial public offering.
Biopharmaceutical firm Parabilis Medicines files for US IPO
Biopharmaceutical company Parabilis Medicines has filed for an initial public offering in the United States, according to a regulatory filing on Tuesday.
Parabilis Medicines IPO Registration Document (S-1)
Parabilis Medicines has filed to go public with an IPO on the NASDAQ